Baird Maintains Outperform on Climb Bio, Raises Price Target to $25

Benzinga Newsdesk www.benzinga.com Positive 91.4%

Neg 0% Neu 0% Pos 91.4%

Baird analyst Colleen Kusy maintains Climb Bio (NASDAQ:CLYM) with a Outperform and raises the price target from $21 to $25.